Menu
Back to Journals » OncoTargets and Therapy » Volume 6
Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer
Authors Chen X, Li Z, Peng H, Jin S, Fu H, Zhu T, Weng X
Received 18 February 2013
Accepted for publication 13 March 2013
Published 14 May 2013 Volume 2013:6 Pages 527—530
DOI https://doi.org/10.2147/OTT.S44162
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Xue-Hui Chen, Zhi-Qiang Li, Hua Peng, Su-Mei Jin, Hui-Qing Fu, Tie-Chui Zhu, Xiao-Gang Weng
The First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of China
Abstract: One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-R1. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-R1 targeting therapy provides a new avenue toward treating liver cancer.
Keywords: IGF, IGF-R1, apoptosis, hepatocellular carcinoma
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.